Home » Stocks » TCRR

TCR2 Therapeutics Inc. (TCRR)

Stock Price: $30.96 USD -0.67 (-2.10%)
Updated Jan 20, 2021 2:07 PM EST - Market open
Market Cap 1.06B
Revenue (ttm) n/a
Net Income (ttm) -61.50M
Shares Out 30.34M
EPS (ttm) -2.40
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day January 20
Last Price $30.96
Previous Close $31.62
Change ($) -0.67
Change (%) -2.10%
Day's Open 31.75
Day's Range 30.56 - 32.70
Day's Volume 1,381,253
52-Week Range 6.01 - 34.07

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
GlobeNewsWire - 1 day ago

CAMBRIDGE, Mass., Jan. 19, 2021 (GLOBE NEWSWIRE) -- TCR2 Therapeutics Inc. (Nasdaq: TCRR) (“TCR2” or the “Company”), a clinical-stage immunotherapy company with a pipeline of novel T cell ther...

GlobeNewsWire - 1 week ago

- Additional data from ongoing gavo-cel Phase 1/2 trial to be presented in 1H21

GlobeNewsWire - 1 month ago

- TC-210 induced tumor regression in all of the first eight patients

GlobeNewsWire - 1 month ago

CAMBRIDGE, Mass., Dec. 11, 2020 (GLOBE NEWSWIRE) -- TCR² Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage immunotherapy company developing a pipeline of novel T cell therapies for patients s...

GlobeNewsWire - 2 months ago

- Consistent progress of TC-210 with interim update from Phase 1/2 trial anticipated in 4Q20

GlobeNewsWire - 3 months ago

CAMBRIDGE, Mass., Sept. 29, 2020 (GLOBE NEWSWIRE) -- TCR2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage immunotherapy company with a pipeline of novel T cell therapies for patients suff...

GlobeNewsWire - 4 months ago

CAMBRIDGE, Mass., Sept. 08, 2020 (GLOBE NEWSWIRE) -- TCR2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage immunotherapy company with a pipeline of novel T cell therapies for patients suff...

GlobeNewsWire - 5 months ago

- TC-210 patient with partial response confirmed by independent central review and tumor regression improved further from 42% to 75%

The Motley Fool - 5 months ago

Their groundbreaking research on CAR T-cell therapies could revolutionize how certain cancers are treated in the future.

Other stocks mentioned: ALLO, CLLS, GILD, NVS
GlobeNewsWire - 5 months ago

CAMBRIDGE, Mass., July 28, 2020 (GLOBE NEWSWIRE) -- TCR2 Therapeutics Inc. (Nasdaq: TCRR) (“TCR2” or the “Company”), a clinical-stage immunotherapy company with a pipeline of novel T cell th...

GlobeNewsWire - 5 months ago

CAMBRIDGE, Mass., July 27, 2020 (GLOBE NEWSWIRE) -- TCR2 Therapeutics Inc. (Nasdaq: TCRR) (“TCR2” or the “Company”), a clinical-stage immunotherapy company with a pipeline of novel T cell th...

The Motley Fool - 5 months ago

The company announced positive interim results for one of its experimental treatments.

GlobeNewsWire - 5 months ago

- TC-210 TRuC-T cell monotherapy induced tumor regression in first five patients

GlobeNewsWire - 5 months ago

CAMBRIDGE, Mass., July 24, 2020 (GLOBE NEWSWIRE) -- TCR2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage immunotherapy company developing a pipeline of novel T cell therapies for patients...

GlobeNewsWire - 7 months ago

CAMBRIDGE, Mass., June 17, 2020 (GLOBE NEWSWIRE) -- TCR2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage immunotherapy company developing the next generation of novel T cell therapies for...

GlobeNewsWire - 7 months ago

CAMBRIDGE, Mass., May 27, 2020 (GLOBE NEWSWIRE) -- TCR2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage immunotherapy company developing the next generation of novel T cell therapies for ...

GlobeNewsWire - 8 months ago

CAMBRIDGE, Mass., May 04, 2020 (GLOBE NEWSWIRE) -- TCR2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage immunotherapy company developing the next generation of novel T cell therapies for ...

GlobeNewsWire - 9 months ago

CAMBRIDGE, Mass., April 15, 2020 (GLOBE NEWSWIRE) -- TCR2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage immunotherapy company developing the next generation of novel T cell therapies fo...

24/7 Wall Street - 9 months ago

The COVID-19 pandemic has changed normal operations for companies across the world as they cope with resource limitations, health precautions and other challenges.

Other stocks mentioned: AVRO, FATE, KNSA, MRSN, NVCR, ORTX, SYBX

About TCRR

TCR2 Therapeutics, a clinical-stage immunotherapy company, develops novel T cell receptor therapies for patients suffering from cancer. The company's lead product candidates include TC-210, mono TCR Fusion Construct T cells (TRuC-T cells) targeting mesothelin positive solid tumors, which initiated in phase I/II clinical trial for the treatment of non-small cell lung cancer (NSCLC), ovarian cancer, malignant pleural/peritoneal mesothelioma, and cholangiocarcinoma; and TC-110 a TRuC-T cell targeting CD19-positive B-Cell hematological malignancies... [Read more...]

Industry
Biotechnology
IPO Date
Feb 14, 2019
CEO
Garry Menzel
Employees
109
Stock Exchange
NASDAQ
Ticker Symbol
TCRR
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 9 analysts, the average rating for TCRR stock is "Strong Buy." The 12-month stock price forecast is 46.89, which is an increase of 51.48% from the latest price.

Price Target
$46.89
(51.48% upside)
Analyst Consensus: Strong Buy